Infectious Diseases

Respiratory syncytial virus in older adults and people with chronic disorders drives substantial winter morbidity. A Portuguese multisociety position recommends RSV vaccination for adults 60 years and older and for younger high-risk patients, endorses coadm...

In Portugal, respiratory syncytial virus prevention in older adults is advancing as a multi-society position endorses vaccination for adults aged 60 years and older and those with chronic disorders. The consensus emphasizes integration into routine immuniza...

Influenza prevention in older adults moves forward with disclosure of the DANFLU-2 protocol comparing high-dose versus standard-dose vaccines in an individually randomized, pragmatic framework. The design emphasizes broad eligibility and real-world outcomes...

Influenza in older adults continues to drive severe illness and healthcare use. A pragmatic, individually randomized comparison of high-dose versus standard-dose influenza vaccination centers on real-world effectiveness outcomes captured via registries, pos...

The DANFLU-2 trial evaluates high-dose versus standard-dose influenza vaccination in older adults using a pragmatic, individually randomized, registry-enabled design. By embedding allocation in routine care and capturing outcomes via national registries, it...

In influenza prevention for older adults, a national pragmatic, individually randomized comparison of high-dose versus standard-dose vaccine outlines a registry-embedded design that aligns outcomes with hospitalizations and mortality. The approach emphasize...

A Portuguese multi-society position consolidates evidence on respiratory syncytial virus infections and recommends RSV vaccination for adults aged >=60 years and for adults with chronic disorders. The guidance addresses eligibility, prioritization when supp...